bs-1112R [Primary Antibody]
glypican 3 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: glypican 3

Immunogen Range: 201-300/580


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 2719

Source: KLH conjugated synthetic peptide derived from human glypican 3

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome. (Also known as glypican 3; Intestinal protein OCI-5; GTR2-2; MXR7; Glypican-3 precursor).

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
FCM(1:20-100)

Predicted Molecular Weight: 65


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Jinno A et al. Syndecan-1 Promotes Streptococcus pneumoniae Corneal Infection by Facilitating the Assembly of Adhesive Fibronectin FibrilsmBio.2020 Dec 11;11(6):e02451-20.Read more>>
  • Jiuxin Zhu. et al. GPC3-targeted and curcumin-loaded phospholipid microbubbles for sono-photodynamic therapy in liver cancer cells. Colloid Surface B. 2021 Jan;197:111358Read more>>
VALIDATION IMAGES

Lane 1: HepG2 lysates; Lane 2: 293T lysates probed with glypican 3 Polyclonal Antibody, Unconjugated (bs-1112R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:10000 for 60 min at 37˚C.